Connect Biopharma Holdings Ltd CNTB
Connect Biopharma Holdings Ltd (Nasdaq: CNTB) is a respiratory drug developer. Its lead program, rademikibart, is in Phase 2 for acute exacerbations of asthma and COPD (Type 2 inflammation). Its next catalyst on record is rademikibart: FDA meeting to align on Phase 3 program (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rademikibart — FDA meeting to align on Phase 3 program (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| rademikibart (Seabreeze STAT ASTHMA) | acute exacerbation of asthma | antibody | Phase 2 |
| rademikibart (Seabreeze STAT COPD) | acute exacerbation of COPD | antibody | Phase 2 |
| rademikibart (Seabreeze STAT IV) | IV add-on for acute exacerbation of asthma/COPD | antibody | Phase 2 |
Recent results and decisions
- Sep 30, 2026met Met primary endpoint: 81% reduction in 28-day treatment failure vs placebo (p=0.0122), with 85% fewer new moderate-severe exacerbations (p=0.030); FEV1 gain at Week 4 of 70 mL not significant (p=0.1607).
Rademikibart significantly reduced the rate of treatment failure by 81% through Week 4 compared to placebo (p=0.0122)
Filing - Sep 15, 2026mixed Primary endpoint of 28-day treatment failure not statistically significant (2.5% vs 7.4%, 66% reduction, p=0.153); key secondary Day 7 post-BD FEV1 significantly improved (+130 mL vs placebo, p=0.023).
Rademikibart reduced the treatment failure rate by approximately 66% over 28 days compared to placebo (p=0.153).
Filing - Apr 23, 2026n/a DMC completed pre-specified interim efficacy analysis of Seabreeze STAT studies with no recommendation to change sample size; no efficacy data disclosed; no safety concerns.
the independent Data Monitoring Committee (DMC) overseeing its Phase 2 Seabreeze STAT asthma and COPD trials ... has completed its review of the pre-specified interim analysis of efficacy with no recommendation for change in the sample size.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 respiratory companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.